Skip to main content

4D Molecular Therapeutics, Inc.

FDMT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001650648

In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.

13F holders, Q3 2023

Institutional positions in 4D Molecular Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
110
+10 vs. Q2 2023
Shares held
41.9M
+664.9K (+1.6%) vs. Q2 2023
Total value
$533.6M
−$211.8M (−28.4%) vs. Q2 2023
New holders
20
42 more added
Sold out
10
33 more reduced

Compare with Q2 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting FDMT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2023: 110 institutions
Q1 2021: 64 institutionsQ2 2021: 56 institutionsQ3 2021: 63 institutionsQ4 2021: 77 institutionsQ1 2022: 80 institutionsQ2 2022: 90 institutionsQ3 2022: 88 institutionsQ4 2022: 96 institutionsQ1 2023: 94 institutionsQ2 2023: 100 institutionsQ3 2023: 110 institutionsQ4 2023: 111 institutionsQ1 2024: 147 institutionsQ2 2024: 143 institutionsQ3 2024: 140 institutionsQ4 2024: 146 institutionsQ1 2025: 126 institutionsQ2 2025: 121 institutionsQ3 2025: 134 institutionsQ4 2025: 153 institutionsQ1 2026: 153 institutionsQ2 2026: 157 institutions
Value heldQ3 2023: $533.6M
Q1 2021: $664.8MQ2 2021: $400.0MQ3 2021: $515.1MQ4 2021: $541.8MQ1 2022: $395.3MQ2 2022: $181.7MQ3 2022: $210.4MQ4 2022: $621.9MQ1 2023: $522.3MQ2 2023: $745.3MQ3 2023: $533.6MQ4 2023: $859.8MQ1 2024: $1.79BQ2 2024: $1.20BQ3 2024: $629.2MQ4 2024: $260.6MQ1 2025: $139.8MQ2 2025: $149.9MQ3 2025: $343.2MQ4 2025: $400.5MQ1 2026: $471.4MQ2 2026: $771.2M
Institutions holding FDMT and their total value by quarter
QuarterHoldersValue
Q2 2026157$771.2M
Q1 2026153$471.4M
Q4 2025153$400.5M
Q3 2025134$343.2M
Q2 2025121$149.9M
Q1 2025126$139.8M
Q4 2024146$260.6M
Q3 2024140$629.2M
Q2 2024143$1.20B
Q1 2024147$1.79B
Q4 2023111$859.8M
Q3 2023110$533.6M
Q2 2023100$745.3M
Q1 202394$522.3M
Q4 202296$621.9M
Q3 202288$210.4M
Q2 202290$181.7M
Q1 202280$395.3M
Q4 202177$541.8M
Q3 202163$515.1M
Q2 202156$400.0M
Q1 202164$664.8M

Institutions, Q3 2023

Shares, value and share of portfolio for each institution holding 4D Molecular Therapeutics, Inc.; share changes are against Q2 2023.

Institutions holding FDMT in Q3 2023
InstitutionSharesValue% of portfolioChange in sharesAction
Tower Research Capital LLC (TRC)1,119$14.2K0.00%−1,913−63.1%Reduced
China Universal Asset Management Co., Ltd.1,078$13.7K0.00%+529+96.4%Added
Cutler Group LP1,000$12.0K0.00%00.0%Unchanged
Allspring Global Investments Holdings, LLC523$6.66K0.00%+523New
Group One Trading, L.P.425$5.41K0.00%−616−59.2%Reduced
US Bancorp264$3.36K0.00%00.0%Unchanged
Simplex Trading, LLC266$3.00K0.00%+266New
Newbridge Financial Services Group, Inc.30$3820.00%00.0%Unchanged
Harbour Investments, Inc.25$3180.00%+25New
Russell Investments Group, Ltd.16$2040.00%−1,110−98.6%Reduced
Great Point Partners LLC0$00.00%−350,000−100.0%Sold out
EcoR1 Capital, LLC0$00.00%−66,978−100.0%Sold out
Blackstone Group Inc.0$00.00%−50,000−100.0%Sold out
Bellevue Group AG0$00.00%−45,000−100.0%Sold out
Ergoteles LLC0$00.00%−35,922−100.0%Sold out
Connor, Clark & Lunn Investment Management Ltd.0$00.00%−21,824−100.0%Sold out
Caption Management, LLC0$00.00%−11,944−100.0%Sold out
Impact Partnership Wealth, LLC0$00.00%−57−100.0%Sold out
Signaturefd, LLC0$00.00%−22−100.0%Sold out
Cubist Systematic Strategies, LLC0$00.00%−1−100.0%Sold out